Janessa Laskin – Health Research BC

Dr. Janessa Laskin, MD

Claim this profile

BC Cancer

Studies Lung Cancer
Studies Cancer
5 reported clinical trials
9 drugs studied

Area of expertise

1Lung Cancer
Janessa Laskin, MD has run 3 trials for Lung Cancer. Some of their research focus areas include:
RET positive
Stage III
NRG1 positive
2Cancer
Janessa Laskin, MD has run 3 trials for Cancer. Some of their research focus areas include:
NRG1 positive
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.
BC Cancer
Image of trial facility.
BC Cancer - Vancouver

Clinical Trials Janessa Laskin, MD is currently running

Image of trial facility.

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting1 award Phase 314 criteria
Image of trial facility.

Atezolizumab

for Cancer

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.
Recruiting1 award Phase 210 criteria

More about Janessa Laskin, MD

Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Janessa Laskin, MD has experience with
  • Atezolizumab
  • Genome Sequencing
  • Seribantumab
  • LOXO-292
  • Carboplatin
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Janessa Laskin, MD specialize in?
Janessa Laskin, MD focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved RET positive patients, or patients who are Stage III.
Is Janessa Laskin, MD currently recruiting for clinical trials?
Yes, Janessa Laskin, MD is currently recruiting for 3 clinical trials in Vancouver British Columbia. If you're interested in participating, you should apply.
Are there any treatments that Janessa Laskin, MD has studied deeply?
Yes, Janessa Laskin, MD has studied treatments such as Atezolizumab, Genome sequencing, Seribantumab.
What is the best way to schedule an appointment with Janessa Laskin, MD?
Apply for one of the trials that Janessa Laskin, MD is conducting.
What is the office address of Janessa Laskin, MD?
The office of Janessa Laskin, MD is located at: BC Cancer, Vancouver, British Columbia V5Z 4E6 Canada. This is the address for their practice at the BC Cancer.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.